Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 4, 2010, Pages 679-686

  Ferrandina, Gabriella ^a,b   Mey, Valentina ^c   Nannizzi, Sara ^c   Ricciardi, Simona ^c   Petrillo, Marco ^a   Ferlini, Cristiano ^b   Danesi, Romano ^c   Scambia, Giovanni ^a   Del Tacca, Mario ^c  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Gemcitabine; Ovarian cancer; Prognosis; Ribonucleotide reductase subunit M2

Indexed keywords

GEMCITABINE; NUCLEOSIDE TRANSPORTER; PACLITAXEL; RIBONUCLEOTIDE REDUCTASE; 5' NUCLEOTIDASE; ANTINEOPLASTIC ANTIMETABOLITE; CARRIER PROTEIN; CIF NUCLEOSIDE TRANSPORTER; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DRUG DERIVATIVE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M2; RRM1 PROTEIN, HUMAN; SLC29A1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; OUTCOME ASSESSMENT; OVARY CANCER; OVARY TUMOR; PRIMARY TUMOR; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN DEGRADATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR CELL LINE;

5'-NUCLEOTIDASE; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL PROLIFERATION; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIERS ESTIMATE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NUCLEOSIDE TRANSPORT PROTEINS; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 75749123899     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1073-y     Document Type: Article

References (38)

1. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun 2008 Cancer statistics, 2008 CA Cancer J Clin 58 71 96 10.3322/CA.2007.0010 18287387
2. M Markman 2008 Pharmaceutical management of ovarian cancer: current status Drugs 68 771 789 10.2165/00003495-200868060-00004 1:CAS:528: DC%2BD1cXmvVeltL4%3D 18416585 (Pubitemid 351550530)
3. JB Vermorken 2008 Second-line randomized trials in epithelial ovarian cancer Int J Gynecol Cancer 18 Suppl 1 59 66 10.1111/j.1525-1438.2007.01161.x 18336403
4. MA Bookman BE Greer RF Ozols 2003 Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs cisplatin and paclitaxel (GOG158) and an update on GOG 182-ICON5 Int J Gynecol Cancer 13 735 740 10.1111/j.1525-1438. 2003.13602.x 1:STN:280:DC%2BD3srpsVCjsg%3D%3D 14675308 (Pubitemid 38235216)
5. G D'Agostino F Amant P Berteloot G Scambia I Vergote 2003 Phase II study of gemcitabine in recurrent platinum- and paclitaxel resistant ovarian cancer Gynecol Oncol 88 266 269 10.1016/S0090-8258(03)00011-8 12648573 (Pubitemid 36331977)
6. G Ferrandina I Paris M Ludovisi G D'Agostino A Testa D Lorusso M Zanghi S Pisconti G Pezzella V Adamo E Breda G Scambia 2005 Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival Gynecol Oncol 98 267 273 10.1016/j.ygyno.2005.04.018 1:CAS:528:DC%2BD2MXmsVWgtbY%3D 15975643 (Pubitemid 41024849)
7. LP Jordheim C Dumontet 2007 Review of recent studies on resistance to cytotoxic deoxynucleoside analogues Biochim Biophys Acta 1776 138 159 1:CAS:528:DC%2BD2sXht12hsLzM 17881132
8. MP Kim GE Gallick 2008 Gemcitabine resistance in pancreatic cancer: picking the key players Clin Cancer Res 14 1284 1285 10.1158/1078-0432.CCR-07- 2247 1:CAS:528:DC%2BD1cXislSku7k%3D 18316544
9. S Pérez-Torras J García-Manteiga E Mercadé FJ Casado N Carbó M Pastor-Anglada A Mazo 2008 Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer Biochem Pharmacol 76 322 329 10.1016/j.bcp.2008.05.011 18589402
10. H Fan A Huang C Villegas JA Wright 1998 The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments Proc Natl Acad Sci USA 94 13181 13186 10.1073/pnas.94.24.13181
11. A Gautam ZR Li G Begler 2003 RRM1-induced metastasis suppression through PTEN-regulated pathways Oncogene 22 2135 2142 10.1038/sj.onc.1206232 1:CAS:528:DC%2BD3sXislyitbo%3D 12687015 (Pubitemid 36539563)
12. H Fan C Villegas A Huang JA Wright 1998 The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation Cancer Res 58 1650 1653 1:CAS:528:DyaK1cXislertbo%3D 9563477
13. BS Zhou R Tsai R Ker J Tsai R Ho J Yu J Shih Y Yen 1998 Overexpression of the transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential Exp Clin Met 16 43 49 10.1023/A:1006559901771 1:CAS:528:DyaK1cXhvVyitL8%3D (Pubitemid 28122554)
14. MS Duxbury EE Whang 2007 RRM2 induces NF-κB-dependent MMP-9 activation and enhances cellular invasiveness Biochem Biophys Res Commun 354 190 196 10.1016/j.bbrc.2006.12.177 1:CAS:528:DC%2BD2sXhtVCls7s%3D 17222798 (Pubitemid 46123218)
15. E Giovannetti M Del Tacca V Mey N Funel S Nannizzi S Ricci C Orlandini U Boggi D Campani M Del Chiaro M Iannopollo G Bevilacqua F Mosca R Danesi 2006 Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine Cancer Res 66 3928 3935 10.1158/0008-5472.CAN-05-4203 1:CAS:528:DC%2BD28XjtVOqs7k%3D 16585222
16. V Sebastiani Sebastiani F Ricci B Rubio-Viqueira P Kulesza CJ Yeo M Hidalgo A Klein D Laheru CA Iacobuzio-Donahue 2006 Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival Clin Cancer Res 12 2492 2497 10.1158/1078-0432.CCR-05-2655
17. V Mey E Giovannetti F De Braud S Nannizzi G Curigliano De Verweij O Cobelli S Pece M Del Tacca R Danesi 2006 In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients Br J Cancer 95 289 297 10.1038/sj.bjc.6603242 1:CAS:528:DC%2BD28Xnsl2iu7s%3D 16868547 (Pubitemid 44187589)
18. C Tibaldi E Giovannetti E Vasile V Mey AC Laan S Nannizzi R Di Marsico A Antonuzzo C Orlandini S Ricciardi M Del Tacca GJ Peters A Falcone R Danesi 2008 Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients Clin Cancer Res 14 1797 1803 10.1158/1078-0432.CCR-07-1364 1:CAS:528: DC%2BD1cXjtleju78%3D 18347182
19. S Nakahira S Nakamori M Tsujie Y Takahashi J Okami S Yoshioka M Yamasaki S Marubashi I Takemasa A Miyamoto Y Takeda H Nagano K Dono K Umeshita M Sakon M Monden 2007 Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer Int J Cancer 120 1355 1363 10.1002/ijc.22390 1:CAS:528:DC%2BD2sXhvVOisr0%3D 17131328 (Pubitemid 46256791)
20. J Souglakos I Boukovinas M Taron P Mendez D Mavroudis M Tripaki D Hatzidaki A Koutsopoulos E Stathopoulos V Georgoulias R Rosell 2008 Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine Br J Cancer 98 1710 1715 10.1038/sj.bjc.6604344 1:CAS:528:DC%2BD1cXlvVWhsb8%3D 18414411 (Pubitemid 351684679)
21. E Giovannetti V Mey L Loni S Nannizzi G Barsanti G Savarino R Del Tacca R Danesi 2007 Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells Pharmacological Res 55 343 349 10.1016/j.phrs.2007.01.003 1:CAS:528:DC%2BD2sXjvFGntrs%3D (Pubitemid 46518163)
22. SK Chatterjee M Bhattacharya JJ Barlow 1981 Evaluation of 5′-nucleotidase as an enzyme marker in ovarian carcinoma Cancer 47 2648 2653 10.1002/1097-0142(19810601)47:11<2648::AID-CNCR2820471121>3.0.CO;2-R 1:CAS:528:DyaL3MXktlymtrw%3D 6266638 (Pubitemid 11113730)
23. X Farré E Guillen-Gomez L Sanchez D Hardisson Y Plaza J Lloberas FJ Casado J Palacios M Pastor-Anglada 2004 Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors Int J Cancer 112 959 966 10.1002/ijc.20524 15386342 (Pubitemid 39507001)
24. G Ferrandina F Legge V Mey S Nannizzi S Ricciardi M Petrillo G Corrado G Scambia 2007 A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge Cancer Chemother Pharmacol 60 459 461 10.1007/s00280-007-0479-7 17429624 (Pubitemid 46944591)
25. HJ Motulsky LA Ransnas 1987 Fitting curves to data using nonlinear regression: a practical and nonmathematical review FASEB J 1 365 374 1:STN:280:DyaL1c%2Fls1SgtQ%3D%3D 3315805
26. E Kaplan P Meyer 1958 Non parametric estimation from incomplete observations J Am Statist Assoc 53 457 481 10.2307/2281868
27. N Mantel 1966 Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 50 163 170 1:STN:280:DyaF287ht1Wgug%3D%3D 5910392
28. DR Cox 1972 Regression models and life tables J R Stat Soc 34 197 220
29. M Sarkar T Han V Damaraju P Carpenter CE Cass RP Agarwal 2005 Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells Biochem Pharmacol 70 426 432 10.1016/j.bcp.2005.05.014 1:CAS:528:DC%2BD2MXlvVWms7s%3D 15950950 (Pubitemid 40905114)
30. JR Mackey RS Mani M Selner D Mowles JD Young JA Belt CR Crawford CE Cass 1998 Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines Cancer Res 58 4349 4357 1:CAS:528:DyaK1cXmsVyqsbo%3D 9766663
31. H Achiwa T Oguri S Sato H Maeda T Niimi R Ueda 2004 Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer Cancer Sci 95 753 757 10.1111/j.1349-7006.2004.tb03257.x 1:CAS:528: DC%2BD2cXpvFOgu7w%3D 15471562 (Pubitemid 39335096)
32. CM Galmarini JR Mackey C Dumontet 2001 Nucleoside analogues: mechanisms of drug resistance and reversal strategies Leukemia 15 875 890 10.1038/sj.leu.2402114 1:CAS:528:DC%2BD3MXkvVOit78%3D 11417472 (Pubitemid 32529886)
33. JD Heidel JY Ching Liu Y Yen B Zhou BSE Heale JJ Rossi DW Bartlett ME Davis 2007 Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo Clin Cancer Res 13 2207 2215 10.1158/1078-0432.CCR-06-2218 1:CAS:528:DC%2BD2sXjs12rtLg%3D 17404105 (Pubitemid 46649891)
34. NM Cerqueira PA Fernandes MJ Ramos 2007 Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents Recent Patents Anticancer Drug Discov 2 11 29 10.2174/157489207779561408 1:CAS:528: DC%2BD2sXhsVWiu74%3D
35. S Chen B Zhou F He Y Yen 2000 Inhibition of human cancer cell growth by inducible expression of human ribonucleotide reductase antisense DNA Antisense Nucleic Acid Drug Dev 10 111 116 1:CAS:528:DC%2BD3cXivVKltL4%3D 10805162
36. Y Lee A Vassilakos N Feng V Lam H Xie M Wang H Jin K Xiong C Liu J Wright A Young 2003 GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors Cancer Res 63 2802 2811 1:CAS:528:DC%2BD3sXkt1ais78%3D 12782585
37. ZP Lin MF Belcourt JG Cory AC Sartorelli 2004 Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors J Biol Chem 279 27030 27038 10.1074/jbc.M402056200 1:CAS:528:DC%2BD2cXkvFGns7w%3D 15096505 (Pubitemid 38812539)
38. MS Duxbury H Ito MJ Zinner SW Ashley EE Whang 2004 RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine Oncogene. 23 1539 1548 10.1038/sj.onc.1207272 1:CAS:528:DC%2BD2cXhsFOhtrg%3D 14661056 (Pubitemid 38406516)